Chairman and CEO of Spermosens exercise TO5 warrants

Spermosens AB (“Spermosens” or the “Company”) today announces that the Chairman of the Board, Ulrik Spork, and the CEO, Tore Duvold, have exercised their respective warrants of series TO5 for the subscription of new shares in the Company.

Ulrik Spork has exercised 6,446,200 warrants, and Tore Duvold has exercised 5,750,000 warrants.

The exercise of the warrants demonstrates continued confidence in Spermosens’ revised strategy, the positive outcome of the clinical study and the long-term potential of the Company’s proprietary diagnostic platform, JUNO-Checked.

As previously communicated, the subscription price per share is SEK 0.0055, and the exercise period runs until 16 June 2025.

For more information, please contact:
Tore Duvold, CEO
[email protected]

Spermosens AB is a pioneering biotechnology company based in Sweden, focused on advancing fertility diagnostics through science driven solutions. The company develops cutting-edge technologies designed to improve fertility outcomes and streamline treatment pathways for individuals and couples facing infertility. The proprietary product, JUNO-Checked, provides a novel diagnostic approach that enhances precision and evaluations by measuring the sperm-egg binding capacity. JUNO-Checked supports more informed clinical decisions and individualized treatments strategies. Driven by a strong commitment to scientific excellence and patient care, Spermosens collaborates with leading research institutions to deliver transformative fertility diagnostics to the global market. The company's shares are listed on the Spotlight Stock Market under the name SPERM (ISIN code SE0015346424). For more information, see www.spermosens.com